Harnessing Real-World Evidence for the Development of Novel Cancer Therapies

Joel Greshock; Martine Lewi; Bert Hartog; Craig Tendler

doi:10.1016/j.trecan.2020.08.006

Harnessing Real-World Evidence for the Development of Novel Cancer Therapies

Trends Cancer. 2020 Nov;6(11):907-909. doi: 10.1016/j.trecan.2020.08.006. Epub 2020 Sep 21.

Authors

Joel Greshock¹, Martine Lewi², Bert Hartog³, Craig Tendler⁴

Affiliations

¹ Janssen Research and Development, Cambridge, MA, USA.
² Janssen Research and Development, Beerse, Belgium. Electronic address: mlewi@ITS.JNJ.com.
³ Janssen Research and Development, Beerse, Belgium.
⁴ Janssen Research and Development, Raritan, NJ, USA.

PMID: 32972882
DOI: 10.1016/j.trecan.2020.08.006

Abstract

Resourcing real-world evidence (RWE) is becoming an increasingly important asset in developing novel therapies for cancer. In this article, an overview of the benefits and challenges of using these data is provided. Through several case examples we highlight future applications and potential.

Keywords: cancer therapy; observational studies; real-world evidence; synthetic control arms.

MeSH terms

Data Interpretation, Statistical
Electronic Health Records / statistics & numerical data
Evidence-Based Medicine / methods*
Humans
Medical Oncology / methods*
Neoplasms / therapy*
Treatment Outcome